title: Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.
abstract: OBJECTIVE
  To review the preoperative and postoperative variables that predict hepatocellular carcinoma (HCC) recurrence following orthotopic liver transplantation (OLT).
  
  
  METHODS
  A collective review of the literature was conducted by searching the MEDLINE database using several key words: hepatocellular carcinoma, recurrence, liver transplantation, and salvage transplantation.
  
  
  METHODS
  Reviews and original articles containing basic scientific observations and long-term clinical outcomes were included.
  
  
  METHODS
  Critical observations from peer-reviewed sources were incorporated in this review.
  
  
  RESULTS
  Overall, 11 studies were reviewed to determine the incidence of HCC recurrence following OLT and to identify prognostic variables of recurrence. Four studies were evaluated to determine the efficacy of salvage transplantation following liver resection.
  
  
  CONCLUSIONS
  Liver transplantation is a viable treatment option for select patients with HCC and end-stage liver disease. However, in approximately 20% of patients, recurrent HCC is the rate-limiting factor for long-term survival. Despite identification of clinical parameters that may stratify patients at high risk and exhaustive preoperative staging, cancer recurrence is likely the result of microscopic extrahepatic disease. With a desperate donor organ shortage, locoregional ablation techniques and resection are being employed in patients on the waiting list to serve as a bridge to OLT. Furthermore, some have advocated aggressive surgical resection of isolated metastasis in both the liver and extrahepatic viscera. Whether these creative strategies confer a survival advantage is unknown; it will require long-term follow-up to determine their efficacy.
authors.affiliation: Dumont-University of California, Los Angeles, Transplant Center, 77-120 CHS, Box 957054, 10833 Le Conte Ave, Los Angeles, CA 90095-7054, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Zimmerman
authors.forename: R Mark
authors.initials: RM
authors.lastname: Ghobrial
authors.forename: Myron J
authors.initials: MJ
authors.lastname: Tong
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Hiatt
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Cameron
authors.forename: Johnny
authors.initials: J
authors.lastname: Hong
authors.forename: Ronald W
authors.initials: RW
authors.lastname: Busuttil
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D002423:Cause of Death; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects* / Q000379:methods; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D011182:Postoperative Care / Q000379:methods; D011237:Predictive Value of Tests; D011300:Preoperative Care / Q000379:methods; D011379:Prognosis; D012086:Reoperation; D018570:Risk Assessment; D016019:Survival Analysis; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000379:methods